Targeting Therapy of Alzheimer’s and Related Neurodegenerative Diseases

Alzheimer’s disease (AD) is the most common age-dependent neurodegenerative disease, which affects over 5 million people in the US and over 35 million people worldwide.

Currently, only four drugs are approved for alleviating symptoms in AD patients, and no new therapy has been approved for AD since 2003.

Academic from: USD 1823.00
Industry from: USD 1823.00
Student from: USD 1534.00

Speakers: Riqiang Yan (Cleveland Clinic Lerner Research Institute), Peter St George-Hyslop (University of Toronto), Don Cleveland (University of California at San Diego), David Holtzman (Washington University) and many more.